![](https://investorshub.advfn.com/uicon/275597.png?cb=1488737828)
Thursday, October 05, 2017 1:53:18 PM
http://www.otipharma.com/wp-content/uploads/2017/03/OT-short-presentation-03-16-2017-V-2.0.pdf
David Platt, Ph.D.
CEO/Chairman of the Board
Dr. Platt is a world-renowned
expert in carbohydrate chemistry
and has founded three publiclytraded
companies, creating nearly
$1B for investors. Prior to Boston
Therapeutics, (OTC: BTHE) from
2001 to 2009, Dr. Platt was a
founder, Chief Executive Officer
and Chairman of the Board at ProPharmaceuticals,
Inc. (OTC:PRWP
and AMEX: PRW, NASDAQ: GALT).
From 1995 to 2000 Dr. Platt was
the founder of International Gene
Group (NASDAQ: IGGI, GLGS)
Yuval Kwintner
B.S., MBA, LL.B
President & Board Member
An experienced entrepreneur and
business executive with proven
abilities in both established
organizations and start-up
ventures. Earned an MBA from
MIT Sloan School of Management,
a B.Sc. from the Technion - Israel
Institute of Technology, and an
LL.B. (JD equivalent) from Tel Aviv
University
Dr. Ben-Zion Weiner, PhD
SCIENTIFIC ADVISORY BOARD CHAIRMAN
Dr. Ben-Zion Weiner was Head of Global
Research and Development at Teva
Pharmaceutical Industries Ltd. for over three
decades, including as a member of the Teva
Executive Committee. He directly oversaw all
pharmaceutical development and regulatory
approval of Teva’s innovative product pipeline.
Dr. Weiner was also responsible for the
development of hundreds of generic products
for the US, European, and other markets. He
received a BSc degree in general chemistry
and biochemistry and an MSc degree in
organic chemistry, graduating with distinction
for both degrees from the Hebrew University,
Jerusalem. He received his PhD degree in
chemistry at the Hebrew University,
Jerusalem, and conducted his post-doctoral
research at Schering-Plough Corporation in
the United States.
Hana Chen-Walden, M.D.
Medical Advisory Board Chairman
Dr. Chen-Walden is an Endocrinologist and
has specialized in regulatory affairs in the
pharmaceutical industry in the U.S and
Europe. Dr. Chen-Walden has more than
35 years of regulatory experience with the
EMEA and in individual European Dr. Chen
Walden received her Doctorate of
Medicine from University of Tel Aviv, Israel.
Dr. Chen-Walden has practiced medicine in
Germany and France
Benjamin Rivnay, Ph.D.
Chief Scientist Director of R&D at Formatech
Managed 50+ projects on formulation
development Vice President, R&D and Lab
Director at Repromedix: Introduced over 50
new test products Senior Investigator and
Program Leader at Procept: Initiated and led
R&D programs Senior Scientist at Neurex
Corporation Associate Professor of
Biochemistry Ph.D., Biochemistry,
Weizmann Institute of Science; B.Sc.,
Biology, Tel Aviv University
Ache Stokelman, B.S.
Senior Advisor
Ache is a veteran of the Biotech industry. He
spent over 20 years at Amgen where he
invented, developed and deployed new
technologies and methods for Process
Development. Earlier in his career he
designed, build and troubleshoot safety and
control systems on offshore platforms. He
obtained a BS in Mechanical Engineering at
The Technion Institute of Technology, Israel
HealthLynked Corp. Announces Second Quarter and First Half 2024 Results: Continued Cost Reductions Set the Stage for Strategic Shift to App-Based Technology Services • HLYK • Aug 16, 2024 8:00 AM
PickleJar Announces Official Name Change and New Ticker Symbol • NREG • Aug 15, 2024 2:23 PM
VAYK's Q2 Profit Added to Accumulated Net Profit of Over $2.2 Million In 18 Months • VAYK • Aug 15, 2024 9:07 AM
Swifty Global Reports Strong Q2 Performance and Prepares for Major Exchange Uplisting • DRCR • Aug 15, 2024 9:04 AM
Mayback's Global Entertainment Signs Global Distribution Agreement with Children's Media Studio • AHRO • Aug 15, 2024 8:45 AM
POET Technologies Reports Second Quarter 2024 Financial Results • POET • Aug 15, 2024 8:04 AM